journal article·2016-07

Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy

Maria Stella Sasso, Giovanna Lollo, Marion Pitorre, Samantha Solito, Laura Pinton, Sara Valpione, Guillaume Bastiat, Susanna Mandruzzato, Vincenzo Bronte, Ilaria Marigo, Jean-Pierre Benoit

Biomaterials· Volume 96
Publisher page

Abstract

Tumor-induced expansion of myeloid-derived suppressor cells (MDSCs) is known to impair the efficacy of cancer immunotherapy. Among pharmacological approaches for MDSC modulation, chemotherapy with selected drugs has a considerable interest due to the possibility of a rapid translation to the clinic. However, such approach is poorly selective and may be associated with dose-dependent toxicities. In the present study, we showed that lipid nanocapsules (LNCs) loaded with a lauroyl-modified form of gemcitabine (GemC12) efficiently target the monocytic (M-) MDSC subset. Subcutaneous administration of GemC12-loaded LNCs reduced the percentage of spleen and tumor-infiltrating M-MDSCs in lymphoma and melanoma-bearing mice, with enhanced efficacy when compared to free gemcitabine. Consistently, fluorochrome-labeled LNCs were preferentially uptaken by monocytic cells rather than by other immune cells, in both tumor-bearing mice and human blood samples from healthy donors and melanoma patients. Very low dose administration of GemC12-loaded LNCs attenuated tumor-associated immunosuppression and increased the efficacy of adoptive T cell therapy. Overall, our results show that GemC12-LNCs have monocyte-targeting properties that can be useful for immunomodulatory purposes, and unveil new possibilities for the exploitation of nanoparticulate drug formulations in cancer immunotherapy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Immune cells in cancer · Immune Cell Function and Interaction · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (65)

Show source-provided references
1. Adoptive cell transfer as personalized immunotherapy for human cancer10.1126/science.aaa4967 ↗
2. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy10.1158/1078-0432.CCR-11-0116 ↗
3. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies10.1158/1078-0432.CCR-13-0380 ↗
4. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-110.1200/JCO.2010.32.2537 ↗
5. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens10.1200/JCO.2008.16.5449 ↗
6. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF10.1002/eji.200939903 ↗
7. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells10.1172/JCI28828 ↗
8. Subsets of myeloid-derived suppressor cells in tumor-bearing mice10.4049/jimmunol.181.8.5791 ↗
9. Coordinated regulation of myeloid cells by tumours10.1038/nri3175 ↗
10. Complexity and challenges in defining myeloid-derived suppressor cells10.1002/cytob.21206 ↗
11. Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways10.1016/j.immuni.2014.10.020 ↗
12. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity10.1182/blood-2007-07-099226 ↗
13. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen10.1016/j.celrep.2012.08.006 ↗
14. Lipid nanocapsules: a new platform for nanomedicine10.1016/j.ijpharm.2009.04.026 ↗
15. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment10.1200/JCO.2007.11.9362 ↗
16. Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer10.1038/sj.bjc.6601518 ↗
17. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG10.1200/JCO.2006.06.0913 ↗
18. Advanced pancreatic carcinoma: current treatment and future challenges10.1038/nrclinonc.2009.236 ↗
19. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity10.1158/1078-0432.CCR-05-0883 ↗
20. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity10.1158/0008-5472.CAN-09-3690 ↗
21. Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma10.1007/s00262-013-1407-9 ↗
22. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice10.1016/j.intimp.2009.03.015 ↗
23. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response10.4049/jimmunol.179.2.977 ↗
24. Aqueous-core PEG-coated PLA nanocapsules for an efficient entrapment of water soluble anticancer drugs and a smart therapeutic response10.1016/j.ejpb.2014.11.012 ↗
25. Core-shell nanoparticulate formulation of gemcitabine: lyophilization, stability studies, and in vivo evaluation10.1007/s13346-014-0206-y ↗
26. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice10.1021/acsnano.5b00510 ↗
27. Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer10.1016/j.biomaterials.2015.03.006 ↗
28. Influence of PEG molecular weight on the drug release and in vitro cytotoxicity of single-walled carbon nanotubes-PEG-gemcitabine conjugates
29. An innovative hydrogel of gemcitabine-loaded lipid nanocapsules: when the drug is a key player of the nanomedicine structure10.1039/c3sm52781f ↗
30. A novel phase inversion-based process for the preparation of lipid nanocarriers10.1023/A:1016121319668 ↗
31. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients10.4049/jimmunol.0803831 ↗
32. Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes10.1182/blood-2009-07-233270 ↗
33. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion10.1038/nm.3105 ↗
34. A new tool to ensure the fluorescent dye labeling stability of nanocarriers: a real challenge for fluorescence imaging10.1016/j.jconrel.2013.06.014 ↗
35. Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications10.1021/mp300370t ↗
36. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor10.1016/j.immuni.2010.05.010 ↗
37. Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice10.1016/j.jconrel.2005.02.028 ↗
38. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen10.1016/j.jconrel.2009.10.022 ↗
39. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles10.1016/j.jconrel.2006.01.006 ↗
40. Exploiting lymphatic transport and complement activation in nanoparticle vaccines10.1038/nbt1332 ↗
41. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer10.1038/ni.2526 ↗
42. Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy10.1016/j.neo.2014.05.011 ↗
43. Antineoplastic agents and the associated myelosuppressive effects: a review10.1177/0897190014546108 ↗
44. Rapid uptake of gold nanorods by primary human blood phagocytes and immunomodulatory effects of surface chemistry10.1021/nn100262h ↗
45. Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice10.1371/journal.pone.0061646 ↗
46. Phosphoinositide-3-kinase-independent contractile activities associated with Fcgamma-receptor-mediated phagocytosis and macropinocytosis in macrophages10.1242/jcs.00235 ↗
47. A role for phosphoinositide 3-kinase in the completion of macropinocytosis and phagocytosis by macrophages10.1083/jcb.135.5.1249 ↗
48. Sequential signaling in plasma-membrane domains during macropinosome formation in macrophages10.1242/jcs.053207 ↗
49. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts10.1073/pnas.0805135105 ↗
50. Understanding biophysicochemical interactions at the nano-bio interface10.1038/nmat2442 ↗
51. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells10.1084/jem.20101956 ↗
52. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function10.1084/jem.20061104 ↗
53. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines10.1016/j.jconrel.2014.05.036 ↗
54. Role of gemcitabine in cancer therapy10.1517/14796694.1.1.7 ↗
55. Safe lipid nanocapsule-based gel technology to target lymph nodes and combat mediastinal metastases from an orthotopic non-small-cell lung cancer model in SCID-CB17 mice10.1016/j.nano.2015.02.010 ↗
56. Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes10.1161/CIRCULATIONAHA.113.002870 ↗
57. Therapeutic siRNA silencing in inflammatory monocytes in mice10.1038/nbt.1989 ↗
58. Selective uptake of single-walled carbon nanotubes by circulating monocytes for enhanced tumour delivery10.1038/nnano.2014.62 ↗
59. Mutant MHC class II epitopes drive therapeutic immune responses to cancer10.1038/nature14426 ↗
60. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens10.1038/nature13988 ↗
61. Neoantigens in cancer immunotherapy10.1126/science.aaa4971 ↗
62. Immune checkpoint blockade in Cancer therapy10.1200/JCO.2014.59.4358 ↗
63. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy10.1126/scitranslmed.3007974 ↗
64. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers10.1158/1078-0432.CCR-10-0733 ↗
65. 6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice10.1007/s00262-015-1702-8 ↗